Selective Bruton tyrosine kinase (BTK) inhibitors, such as ibrutinib and zanubrutinib, have been widely used as effective and well-tolerated treatments for chronic lymphocytic leukemia (CLL) [2] and mantle cell lymphoma (MCL) [3]. Here, BTK is linked to mantle cell lymphoma.